Related Experiment Video

Updated: Aug 17, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

Rajiv Agarwal1, Chandan Saha, Meher Battiwala

  • 1Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. ragarwal@iupui.edu

Kidney International
|June 16, 2005
PubMed
Abstract

Insights

Peroxisome proliferator activated receptor-gamma (PPAR-gamma) agonists did not significantly reduce proteinuria in patients with diabetic nephropathy compared to sulfonylureas. Further research is needed to confirm renal protection benefits.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD).
  • Animal studies suggest peroxisome proliferator activated receptor-gamma (PPAR-gamma) agonists may offer glucose-independent renal protection.
  • This study investigated the potential of PPAR-gamma-based therapy for renal protection in diabetic nephropathy.

Purpose of the Study:

  • To compare the efficacy of PPAR-gamma-based therapy (pioglitazone) versus sulfonylurea-based therapy (glipizide) in reducing proteinuria in patients with diabetic nephropathy.
  • To assess whether PPAR-gamma agonists provide greater proteinuria reduction than traditional antidiabetic agents.

Main Methods:

  • An open-label, blinded endpoint trial involving 44 patients with overt diabetic nephropathy.
  • Participants were randomized to receive either pioglitazone or glipizide, aiming for similar glycemic control.
  • Proteinuria was measured via 24-hour urine collections monthly for 4 months.

Main Results:

  • Neither pioglitazone nor glipizide demonstrated a statistically significant reduction in proteinuria over the 4-month study period.
  • The pioglitazone group showed a trend towards reduction, while the glipizide group showed a slight increase in proteinuria.
  • Baseline proteinuria, diastolic blood pressure, and serum albumin were identified as independent predictors of proteinuria reduction.

Conclusions:

  • The study found no significant reduction in proteinuria with PPAR-gamma agonist therapy in patients with advanced diabetic nephropathy over 4 months.
  • The findings suggest that larger, longer-duration studies are necessary to establish the renal protective effects of PPAR-gamma agonists.
  • These data can inform the design of future clinical trials investigating PPAR-gamma agonists for diabetic nephropathy treatment.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...